Akums Q1FY27: consolidated PAT surges 56% YoY to ₹101 Cr as margins expand, exports miss

Akums Drugs' consolidated Q1 FY27 (June quarter) print showed profit after tax of ₹100.98 Cr, up 56.1% YoY from ₹64.69 Cr and up 24.2% QoQ from ₹81.34 Cr, on revenue of ₹1,166.63 Cr, up 13.9% YoY and roughly flat (+0.8%) QoQ. Net margin expanded to 8.44% from 6.16% a year ago and 6.82% last quarter; operating margin (EBITDA/revenue) rose to an estimated ~15.0% from ~12.6% YoY. Neither the current nor the year-ago quarter carried exceptional items, so the growth is on a clean, unadjusted basis. The drivers line up closely with management's May 2026 guidance. CDMO external revenue grew 18.6% YoY to ₹964.21 Cr, ahead of the guided "double-digit volume growth." The API segment's loss narrowed to ₹8.15 Cr from ₹10.65 Cr a year ago and from ₹16.75 Cr last quarter, consistent with management's stated goal to "significantly reduce losses" — though full-year API profitability remains unconfirmed, per management's own earlier caveat. Domestic branded formulations grew 7.3% YoY, broadly tracking the guided IPM-level pace. International branded formulations (exports), however, fell 1.5% YoY to ₹34.55 Cr against a guided double-digit export growth target — a clear miss on that specific line even as the consolidated headline beat. A divergence worth flagging: standalone (parent-only) PAT was almost flat YoY at ₹44.84 Cr (-0.06%) even as standalone revenue grew 18.0% YoY — nearly all of the consolidated profit growth is coming from subsidiaries, not the parent entity. No quarter-specific street consensus could be located; full-year FY27 analyst PAT-growth estimates sit around 15-20%, a pace this quarter's +56% YoY print is running well ahead of, though a single quarter isn't directly comparable to an annual estimate. The board also disclosed a fresh income-tax demand of ₹156.02 Cr for the FY19-25 block period tied to the 2025 search-and-seizure action (company has appealed, deposited ₹4.70 Cr under protest, and maintains no adjustment is needed), and subsequent to quarter-end, subsidiary Pure and Cure Healthcare agreed to acquire Oriflame India's manufacturing business for ₹56 Cr, extending the group into color cosmetics, skincare and wellness. Going into Q2, the watch items are whether exports recover toward the guided double-digit pace after this quarter's decline, whether API segment losses keep narrowing toward full-year profitability, and whether CDMO margins begin moving toward the "high teens" management has guided for the medium term as new international contracts and the ₹300 Cr FY27 capex programme (oral solids expansion, injectables, inorganic moves like Oriflame) ramp up.